Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Wakamoto Pharmaceutical is a Japanese specialty pharmaceutical company focused on gastrointestinal and digestive health products, including its flagship Wakamoto brand of digestive enzyme supplements. The company operates primarily in Japan's domestic pharmaceutical market with a niche position in OTC digestive aids and prescription gastrointestinal medications. Despite stable revenue, the company faces margin pressure from generic competition and elevated R&D/SG&A expenses relative to its revenue base.
Wakamoto generates revenue through direct sales of branded OTC digestive products to Japanese pharmacies and retailers, prescription drug sales through hospital and clinic channels, and contract manufacturing for third parties. The company's 46.5% gross margin reflects moderate pricing power in niche gastrointestinal segments, but negative operating margins indicate significant overhead from R&D, regulatory compliance, and distribution infrastructure. Competitive advantages include established brand recognition in Japan's aging demographic (digestive health focus aligns with elderly population needs) and proprietary enzyme formulations, though these are increasingly challenged by generic alternatives and larger pharmaceutical competitors.
Japanese yen exchange rate movements (impacts import costs for raw materials and relative valuation for foreign investors)
Domestic pharmaceutical pricing reforms by Japan's Ministry of Health, Labour and Welfare (biennial drug price revisions)
New product approvals or pipeline developments in gastrointestinal therapeutics
Demographic trends in Japan's aging population (65+ cohort drives digestive health product demand)
Generic competition intensity for key prescription products
Japan's biennial drug pricing system systematically reduces reimbursement rates for established pharmaceuticals, creating persistent margin pressure on prescription products
Demographic headwinds beyond 2030s as Japan's population decline accelerates, potentially shrinking the absolute addressable market despite aging trends
Generic substitution policies promoted by Japanese government to control healthcare costs, eroding branded product pricing power
Large multinational pharmaceutical companies (Takeda, Astellas, Daiichi Sankyo) have superior R&D resources and can out-invest in gastrointestinal therapeutic development
Chinese and Indian generic manufacturers entering Japanese market with lower-cost alternatives to Wakamoto's OTC and prescription products
Limited international diversification leaves company vulnerable to Japan-specific regulatory changes and market saturation
Negative free cash flow of $1.0B annually is unsustainable without asset sales, equity raises, or operational turnaround - current cash burn rate threatens liquidity within 2-3 years despite strong current ratio
Elevated capex of $0.5B relative to revenue base suggests either necessary facility upgrades or inefficient capital allocation that isn't generating returns (ROA only 1.9%, ROE 2.6%)
low - Pharmaceutical demand, particularly for gastrointestinal and digestive health products, is relatively non-discretionary and driven by medical need rather than economic conditions. Japan's aging demographics provide structural demand support regardless of GDP fluctuations. However, severe recessions could pressure OTC segment sales if consumers delay non-urgent health purchases.
Moderate sensitivity through two channels: (1) Valuation multiples - as a low-growth, low-margin pharmaceutical company, rising Japanese government bond yields make the stock less attractive on a relative basis, compressing P/E multiples. (2) Financing costs - though debt/equity is minimal at 0.01, negative free cash flow may require future debt financing where rising rates would increase costs. The Bank of Japan's monetary policy stance is more relevant than US rates given domestic focus.
Minimal - The company has negligible debt (0.01 D/E ratio) and a strong current ratio of 4.00, indicating substantial liquidity. However, negative operating cash flow of $0.6B and negative FCF of $1.0B suggest the company is burning through cash reserves. If this continues, future credit access and terms could become relevant, but currently credit conditions have limited direct business impact.
value - The stock trades at 0.9x book value and 1.2x sales, suggesting deep value investors are attracted to the discount despite operational challenges. The 30.5% one-year return indicates some investors are betting on turnaround potential or asset value. However, negative operating margins and cash flow make this unsuitable for income or quality-focused investors. The profile attracts contrarian value investors willing to accept operational risk for potential mean reversion.
moderate - As a small-cap Japanese pharmaceutical company with limited liquidity, the stock likely experiences moderate volatility driven by yen fluctuations, sector rotation, and company-specific news. The 12.4% three-month return vs 1.0% six-month return suggests episodic volatility around catalysts. Healthcare stocks generally have lower beta than market, but operational challenges and cash burn create idiosyncratic risk.
